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Objectives: The objectives of the study were to test the hypothesis that hyperbaric
levels of oxygen enhance the sensitivity of a sarcoma cell line to doxorubicin
(Adriamycin) both in vitro and in vivo in a rat model of pulmonary metastases and
to test the feasibility of arterialization of mixed venous blood by direct injection of
aqueous oxygen into the pulmonary artery in a rat model.
Methods: Rat sarcoma (MCA-2) cells were incubated in the presence of increasing
concentrations of doxorubicin (0.1-2.0 mol/L). A dose-dependent toxicity rela-
tionship at 12 hours of treatment was examined with and without pretreatment with
hyperbaric oxygen (3.7 atm absolute for 1.5-3.5 hours). In vivo, Sprague-Dawley
rats (n  24) were injected intravenously with 106 MCA-2 cells, and the lung
tumors were allowed to mature for 14 days. At that time the animals were divided
into four groups: control (no treatment), doxorubicin at 2 mg/kg, hyperbaric oxygen
(oxygen at 2 atm absolute for 30 minutes), and hyperbaric oxygen plus doxorubicin.
Seven days after treatment, the numbers of lung nodules were counted and the lung
weights were determined. In additional rats (n  7), aqueous oxygen (1 mL
oxygen/g saline solution) was infused into the pulmonary artery to determine
whether arterialization of mixed venous blood was comparable to pulmonary artery
oxygenation with a hyperbaric chamber (n  7).
Results: Hyperbaric oxygen plus doxorubicin produced significantly greater cytol-
ysis of MCA-2 cells (P  .01) than did doxorubicin alone. Hyperbaric oxygen plus
doxorubicin also significantly decreased the number of lung metastases and the lung
weight relative to doxorubicin alone (P  .01 and P  .01, respectively). The
feasibility of arterialization of mixed venous blood (100 mm Hg) with aqueous
oxygen infusion was demonstrated.
Conclusions: Hyperbaric oxygen enhanced the chemotherapeutic effect of doxoru-
bicin both in cell culture and in the rat model. Aqueous oxygen infusion can be used
to oxygenate mixed venous blood at levels similar to those obtained with the use of
a hyperbaric chamber.
Tissue hypoxia contributes to the radioresistance of many tumors andmay also reduce their sensitivity to some chemotherapeutic agents. Avariety of approaches have been used to improve oxygen delivery inplasma, including the use of hyperbaric oxygen (HBO), hemoglobinpreparations, and perfluorochemicals.1-5 The relatively high levels ofoxygen deliverable with HBO make this approach attractive, and the
results of many studies support the hypothesis that HBO reduces the radioresistance
of certain types of tumors. Recent studies also suggest that HBO may enhance the
efficacy of doxorubicin and alkylating agents in the treatment of hypoxic tumors.6-9
Application of HBO is limited by lack of control of PaO2, difficulties in treatment
during exposure, middle ear barotrauma, expense, and availability. For patients with
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lung tumors, tissue hypoxia may be a particular problem
because of the dual factors of impaired respiratory function
and perfusion of tissue with mixed venous blood.
We recently developed a new method for regional per-
fusion of tissues with blood oxygenated by intra-arterial
infusion of aqueous oxygen. The miniature size of the
capillary used to deliver aqueous oxygen, the physiologic
interface for introduction of oxygen (saline solution and
blood mixing), and the hyperbaric levels of oxygen achiev-
able provide multiple potential advantages relative to con-
ventional membrane oxygenators.10-11
These studies were designed to test the feasibility of the
use of aqueous oxygen infusion for potential enhancement
of conventional treatment of lung tumors. Sarcoma cell
cultures and a rat model of sarcoma pulmonary metastases
were studied to determine whether HBO potentiates the
toxicity of doxorubicin.
Methods
In Vitro Studies
For the purpose of evaluating the effect of high levels of oxygen on
culture cells, two cell lines were used: MCA-2, a highly undiffer-
entiated rat-derived rhabdomyosarcoma cell line, and H9C2, a line
of embryonic rat–derived cardiac myocytes. The latter were also
Figure 1. HBO effect on embryonic cardiac myocyte (H9C2) growth curves. Diamonds indicate normal growth curve
in air; squares indicate reduced growth with toxic effect of HBO. Data points represent mean; error bars represent
SE; number of observations  29.
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studied because of the known cardiac toxicity of doxorubicin. The
cells were cultured in 6-well dishes at 37°C, and normal growth
curves were determined by counting cells at 12, 24, 36, 72, and 96
hours. Cells were counted with the Trypan blue exclusion method,
and the results were plotted against time. The lactate dehydroge-
nase (LDH) activity in the culture medium was determined at the
same times by spectrophotometry, which was also a reliable
method of confirming the cell counts.12-14
After they reached 75% confluence, a group of cells from both
populations were treated with HBO. For this purpose a hyper-
baric chamber with multiple ports of access connected to an
oxygen tank was used. The cells were placed inside the cham-
ber, and oxygen at 40 psi was administered for either 1.5, 2.5,
or 3.5 hours. After the procedure, the cells were immediately
counted; cell counts and LDH determinations were also per-
formed 12, 24, 36, 72, and 96 hours after initiation of HBO.
Doxorubicin across a range of concentrations (0.1-2 mol/L)
was added to the culture medium, and the total number of cells
and the LDH activity in the medium were assessed 12 hours
after treatment.
To test the hypothesis that HBO may act as a chemosensitizer
of tumor cells, an initial dose of HBO (1.5 or 3.5 hours at 40 psi)
was administered to MCA-2 cells in the hyperbaric chamber. They
were then immediately treated with increasing concentrations of
doxorubicin (0.1-2 mol/L). Cells were counted and LDH activity
was measured 12 hours after treatment with doxorubicin.
Figure 2. HBO effect on rat sarcoma cell (MCA-2) growth curves. Triangles indicate normal growth curve in air;
circles indicate increased growth after 1.5 hours HBO for up to 36 hours. Data points represent mean; error bars
represent SE; number of observations  28.
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Figure 3. Dose-dependent responses of embryonic cardiac myocytes (H9CA) and sarcoma cells (MCA-2) to
doxorubicin. A, Cell death of H9C2 cells even at minimal doxorubicin doses. B, LDH activity in H9C2 cells (which
mirrors cell death) showed increasing activity with increasing doxorubicin doses.
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Figure 3. Cont’d. C, Cell death of MCA-2 cells even at minimal doxorubicin doses. D, LDH activity in MCA-2 cells
(which mirrors cell death) showed increasing activity with increasing doxorubicin doses. Ctr, Control; m,
micromolar; c%, concentration.
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To gain insight into a potential mechanism by which HBO may
sensitize cells to doxorubicin, MCA-2 cells were treated in ad-
vance with 0.2-mol/L mitomycin, a drug known to block the cells
in the S phase of the cell cycle. A single 0.2-mol/L dose of
mitomycin was followed by administration of HBO alone or in
combination with doxorubicin as described previously. Cell counts
were done at 24, 36, and 72 hours.
In Vivo Studies
All the protocols were approved by the Wayne State University
School of Medicine institutional review board. All the animals
were housed and studied in a facility approved by the American
Association for Accreditation of Laboratory Animal Care. Humane
care was provided to all animals in accordance with the “Principles
of Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources, National Research Council, and published by the
National Academy Press, revised 1996.
To determine the PO2 achieved in the pulmonary artery (PA), 7
Sprague-Dawley rats received pentobarbital anesthesia and were
treated with HBO in the hyperbaric chamber with oxygen at 25 psi
for 30 minutes. Blood samples were collected from both arterial
and PA sites by a catheter placed in a peripheral artery (carotid
artery) and by a catheter placed at the base of the PA through a
19-gauge catheter through a thoracotomy. Blood gas samples were
analyzed with an automated system (model 1312; Instrumentation
Laboratories). The baseline values of PO2 and PCo2 both in the PA
and at the arterial site were measured at time 0 and after 10 and 30
minutes of HBO administration in the chamber. Lungs of animals
that received HBO were examined histologically.
For the aqueous oxygen method, Sprague-Dawley rats were
anesthetized with pentobarbital, placed on mechanical ventilation,
and subjected to left thoracotomy. A 19-gauge needle catheter was
placed through the right ventricular outflow tract into the base of
the PA. A 4F sheath was advanced through the transventricular
catheter in the PA, and an aqueous oxygen solution containing 1.0
mL oxygen per gram of saline solution (3.4 MPa oxygen pressure)
was infused directly into the PA at a rate of 1 mL/min. Blood
samples were withdrawn from the catheter at time 0 to establish a
baseline value and at 10 and 30 minutes after the aqueous oxygen
treatment. The PO2 and PCo2 values in the PA were plotted. A
4-MHz prototype microbubble detector (ZEVEX International,
Inc, Salt Lake City, Utah) mounted on the distal end of the circuit
was used to detect microbubble formation.
Sprague-Dawley rats were randomly assigned to four different
groups. The first group (n  6) was injected at time 0 under
pentobarbital anesthesia directly into the jugular vein with 1 mL of
a suspension containing 1  106 MCA-2 cells/mL. At 14 days
after the treatment, 3 of the animals were killed to assess the
progression of the lung disease, and all the visible morphologic
changes were noted. At 21 days the rest of the animals were killed,
Figure 4. HBO as chemosensitizer. Cell counts with 1.5 hours of pretreatment HBO show enhanced sarcoma cell
(MCA-2) death relative to treatment of sarcoma cells with doxorubicin only or pretreatment with 3.5 hours of HBO.
d, Micromolar doxorubicin dose.
General Thoracic Surgery Petre et al
90 The Journal of Thoracic and Cardiovascular Surgery ● January 2003
G
TS
and the number of lung nodules and the total lung weight were
determined for each. The MCA-2 tumor cell line, developed by
Nagashima and colleagues,15 is highly reproducible. All animals
have bilateral lesions, and all die by 4 weeks.16
The second group (n  6) was subjected to the same treatment
with MCA-2 cells. At 14 days after the initial treatment, the
animals were subjected to high levels of HBO (oxygen at 25 psi for
30 minutes). At 21 days after the initial treatment, these animals
were also killed and the same parameters were measured.
The third group (n  6) was also subjected to MCA-2 admin-
istration. At 14 days, 2 mg/kg doxorubicin solution was given
intrajugularly. At 21 days, the animals were killed and the same
parameters were measured. The dose of doxorubicin given was
the usual chemotherapeutic dose, which does not cause cardio-
toxicity.
The fourth group (n 6) was subjected to a combination of the
previous two methods. At 14 days after the MCA-2 cell adminis-
tration, the animals were exposed to oxygen at 25 psi for 30
minutes and immediately thereafter to 2 mg/kg doxorubicin (1 mL)
administered intrajugularly. At 21 days, the animals were killed
and the same parameters as in the previous groups were deter-
mined.
Postmortem Studies
After 21 days, animals from all four treatment groups were killed
to determine the effects of HBO on tumor growth and the efficacy
of the HBO as a chemosensitizer to doxorubicin. The lungs were
removed, and the total number of metastatic nodules in both lungs
was determined and plotted. The total lung weight was also mea-
sured, and the results were compared with the average weight in
the control group. The investigators were not blinded to the treat-
ments at the time of analysis.
Data Analysis
An unpaired t test assuming unequal variances was used to com-
pare values across time with baseline values for both cell treatment
groups and in vivo studies. Mean values are expressed as mean 
1.96 SE. For comparisons of more than two groups, a 2–way
unbalanced analysis of variance was used, with a Bonferroni-type
correction applied to P values.
Results
In Vitro Studies
HBO exerted a toxic effect on H9C2 cells (rat embryonic
cardiac myocytes), as reflected in a descending growth
curve relative to cells cultured in air. The difference was
statistically significant at 24 hours (10.809  1.861  104
cells vs 5.7142  0.714  104 cells, P  .01) and at 36
hours (14.809 1.761 104 cells vs 3.9523 0.847 104
cells, P  .01; Figure 1). MCA-2 cells (rat-derived rhab-
domyosarcoma) exhibited biphasic behavior. At 40 psi for
Figure 5. Mitomycin effect on sarcoma cells (MCA-2) treated with HBO and doxorubicin. Mitomycin blocks
HBO-induced proliferation. There is no significant difference between doxorubicin-treated cells and cells treated
with mitomycin before HBO and doxorubicin administration. Horizontal line fill, Doxorubicin only at 0.2 mol/L;
gray fill, doxorubicin plus HBO; dotted fill, doxorubicin and HBO with mitomycin pretreatment.
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1.5 hours, HBO was associated with an early proliferative
response (at 24 hours 188.0769  44.633  104 cells with
no treatment vs 305.384 110.406 104 cells treated with
HBO, P  .01; Figure 2). At longer durations of HBO, loss
of cell viability was observed (at 24 hours 168.03 
20.838  104 cells treated with oxygen at 40 psi for 2.5
hours and 109.445  11.675 104 cells treated with oxygen
at 40 psi for 3.5 hours).
Doxorubicin was toxic to both H9C2 and MCA-2 cells at
even a minimal dose (0.1 mol/L), and cell death increased
in a dose-dependent manner for both cell populations. LDH
levels had corresponding increases at higher doses of doxo-
rubicin (Figure 3, A-D).
MCA-2 cells treated with oxygen at 40 psi for 1.5 hours
and 0.1-mol/L doxorubicin exhibited enhanced lysis
(18.642  2.247  104 cells, corresponding to an average
viability of 42%) relative to cells treated with either 0.1-
mol/L doxorubicin alone (29.9  11.6  104, average
viability 70%, P .01) or longer HBO (oxygen at 40 psi for
3.5 hours) and 0.1-mol/L doxorubicin (8.4  0.7  104
cells, average 50% viability, P  .01; Figure 4).
Mitomycin blocked the proliferative effect associated
with oxygen at 40 psi for 1.5 hours. Sarcoma cell death with
0.1 mol/L-doxorubicin was not significantly different
from the group treated with mitomycin and HBO plus
doxorubicin (at 24 hours, 55  10.2  104 cells vs 56.72 
14.61 104 cells, P  .7935; Figure 5).
In Vivo Animal Studies
Oxygen tensions. The PA PO2 values in the mixed PA
venous blood obtained after HBO treatment with oxygen at
25 psi were higher (143.642 71.478 mm Hg at 10 minutes
and 187.92  20.268 mm Hg at 30 minutes) than the
baseline PO2 (44.23  3.645 mm Hg) (Figure 6). The mean
PaO2 achieved similar directional changes (411.54  59.65
mm Hg after 30 minutes vs 91.254  15.263 mm Hg
baseline). No microscopic injuries were noted in the lungs
of the animals that received HBO. The PA PO2 values
obtained after aqueous oxygen infusion were comparable to
those seen after HBO administration (140.224 16.22 at 10
minutes of aqueous oxygen infusion in the PA and 211 
5.0 at 30 minutes). The same results were obtained for PaO2
values after aqueous oxygen infusion (156.071  17.7609
mm Hg for 5 minutes of aqueous oxygen infusion and
392.714  75.606 mm Hg for 10 minutes vs baseline value
90.2  4.2 mm Hg).
Metastases. The mean number of metastases in group 1
(tumor cells only), 73.1666  12.166 metastases, was sig-
nificantly greater than the numbers of metastases in group 3
Figure 6. PA Po2 after HBO administration by hyperbaric chamber. Note increases in PA Po2 at 10 (10 ) and 30
minutes (30 ) relative to baseline.
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(doxorubicin only), 24.833  20.566 metastases (P  .01),
and group 4 (HBO before doxorubicin), 9.16  3.76 me-
tastases (P  .01; Figure 7, A). Similarly, mean lung weight
was significantly higher in group 1 (3.247 0.0015 g) than in
group 3 (2.696  0.0001 g, P  .01) and group 4 (2.441 
0.0001 g, P  .01; Figure 7, B). HBO only (group 2) was not
associated with significant changes in the number of nodules
(72.5  9.5, P  .7329) and average lung weight (3.23 
0.002 g, P  .5483) relative to group 1. HBO before doxoru-
bicin (group 4) was associated with significant decreases in
both the number of nodules (P  .01) and the mean lung
weight (P  .01) relative to doxorubicin alone (group 3).
Figure 7. In vivo response to doxorubicin and HBO in rat metastatic lung sarcoma model. A, Number of metastases
per individual lung decreased significantly when treated with doxorubicin (Doxo) alone and then had significant
further decrease when treated with HBO and doxorubicin. B, Changes in individual lung weights correspond with
decreases in metastatic tumor nodules. No treat., No treatment; Ctr, control.
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Discussion
HBO at 3.7 atm absolute for 1.5 hours sensitized a rhabo-
myosarcoma cell line (MCA-2) to the cytotoxic effects of
doxorubicin, including the lowest level of the drug exam-
ined (0.1 mol/L). HBO also enhanced the in vivo chemo-
therapeutic response of MCA-2 metastatic lung tumors to
doxorubicin in terms of both the number of tumors and lung
weight 2 weeks after treatment.
At the 0.1-mol/L drug level studied in cell culture, only
mild toxicity to cardiomyocytes (H9C2) was observed un-
der normoxic conditions. Considering the toxicity to cardio-
myocytes of HBO (3.7 atm absolute for 1.5 hours) itself in
our study and the known role of oxygen radicals in doxo-
rubicin cardiotoxicity, the combination of doxorubicin and
HBO would also be expected to enhance the drug’s cardio-
toxicity. In a potentially relevant study, Monstrey and as-
sociates17 demonstrated experimentally that HBO does en-
hance oxygen-derived free radical–mediated toxicity of
doxorubicin to other normal tissues. Thus the clinical addi-
tion of HBO to doxorubicin may not change the risk-benefit
ratio of the drug.
However, regional HBO treatment provided with aque-
ous oxygen infusion can be used in a highly site-specific
manner to avoid elevating systemic oxygen levels. Such an
approach might allow the use of doxorubicin at levels that
produce minimal cardiotoxicity. Although regional infusion
of a chemotherapeutic agent can be performed, exposure of
systemic tissues to the agent will nevertheless occur.
The mechanism through which HBO potentiated the
toxic effects of doxorubicin in our studies is unclear. Oxy-
gen radical production may be enhanced, but the relation-
ship between PO2 and generation of oxygen radicals may be
quite complex, as has been shown by DeGroot and Noll.18
As an alternative mechanism, perturbation of the cell
cycle of prostate cancer cells by HBO, with cell cycle
synchronization and entry into G2 and M phases, was found
by Kalns and Piepmeier19 and suggested to potentially in-
crease the efficacy of chemotherapy or radiation. The cause
for proliferation of MCA-2 cells in this study is unknown.
One hypothesis is that HBO acts as a second messenger to
speed entry into G2 and M phases. In this study, stimulation
of MCA-2 cells by HBO (3.7 atm absolute for 1.5 hours)
caused cells to proliferate earlier than cells grown in air. The
fact that enhancement of sensitivity to doxorubicin was
found to occur after rather than during HBO exposure
provides some support for this concept. Perhaps even more
relevant, mitomycin, an agent that inhibits cell proliferation,
reduced HBO enhancement of doxorubicin toxicity to
MCA-2 cells. In addition, there was no increase in cell death
when HBO was given after doxorubicin.
Under hyperbaric conditions, the PO2 of mixed venous
blood can approach normal levels for PaO2, as we found in our
in vivo study. Similarly high levels were achievable with aqueous
oxygen infusion into the PA. The potential exists for aqueous
oxygen infusion into mixed venous blood to enhance PO2 to
levels even higher than those of arterial samples during HBO.
Therefore the potential use of the new technology to attenuate
hypoxia within lung tumors perfused by mixed venous blood
and to enhance drug or radiation therapy is attractive.
Isolated perfusion studies by Weksler and coworkers20
with higher doses of doxorubicin than in this model dem-
onstrated significant decreases in tumors per lung. Combin-
ing HBO with high-dose doxorubicin offers the possibility of
an additive effect of HBO to the standard doxorubicin dose.
Conclusion
At certain concentrations (1.5 hours at 40 psi) HBO en-
hanced the proliferation of rat rhabdomyosarcoma cells in
vitro. HBO also increased the tumoricidal action of doxo-
rubicin. Doxorubicin could be used in conjunction with
HBO to obtain the same effect as higher doxorubicin doses.
The chemosensitizing effect of HBO was reproduced in
a metastatic rat lung tumor model. High levels of oxygen
enhanced chemotherapy action, probably by stimulating
tumor growth. Increased oxygen can oxygenate mixed ve-
nous blood (in the PA) to levels similar to those achieved by
use of a hyperbaric chamber. Aqueous oxygen is a potential
method to raise the oxygen level to arterial levels in the PA
and to hyperbaric levels in the remainder of the body. With
this hyperbaric cell effect, aqueous oxygen could enhance
the effect of regional or systemic chemotherapy in vivo.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). I did not under-
stand exactly how you created that hyperbaric situation in vivo.
Some animals were treated in a hyperbaric chamber whereas
others had this infusion technique?
Dr Baciewicz. With regard to the animals that were adminis-
tered tumor cells, gave hyperbaric levels of oxygen on day 14.
These animals were quite ill, so we administered the oxygen by the
hyperbaric chamber technique. We had hoped to use the aqueous
oxygen technique for those animals, but it was difficult to place a
4F catheter into the PA, especially when all these animals were
dead 7 days later. We were not able to do what we had hoped. We
did demonstrate with the aqueous oxygen technique that we could
obtain the same levels of oxygen in the pulmonary as with the
hyperbaric chamber. We need a larger animal model to look
further at this. The aqueous oxygen has already been used for
patients with myocardial infarction, with infusion into left coro-
naries and right coronaries, with good phase I data. We should be
able to duplicate the aqueous oxygen technique in a different
model.
Dr Stephen G. Swisher (Houston, Tex). I saw some nice
differences there. Did you look at this statistically as well?
Dr Baciewicz. Yes.
Dr Swisher. Was it statistically significant?
Dr Baciewicz. Yes, it was statistically significant.
Dr David H. Harpole, Jr (Durham, NC). I have a follow-up
question. Obviously, poor perfusion is a major problem with
respect to getting the chemotherapy to the hypoxic areas of the
tumor. In addition, one needs oxygen to create the free radicals for
the DNA damage from radiation therapy to induce apoptosis and
cell death. So have you thought about using this as a radiation
adjunct? I think it would have a tremendous effect. Carbogen
breathing, if you are familiar with those studies, has shown in-
creased efficacy for radiation therapy, so I think that this also
would have a use in that field.
Dr Baciewicz. Thanks for the question. That was actually the
main idea for the project, that radiosensitivity would be tremen-
dously increased by delivering hyperbaric levels of oxygen or
increased oxygen to the lung. We are about to start those studies.
Work with isolated lung perfusion and doxorubicin has been done
in this tumor model. So we are hoping to put all three things
together. It is difficult in our institution to give radiation therapy
and HBO to these animals. That was our original intent for the
study. This work with the chemotherapeutic agent was a spin-off,
and we are hoping to get the radiation part going soon. It is an
excellent question.
Dr Peter Goldstraw (London, United Kingdom). We know
that the pulmonary toxicity of chemotherapeutic agents can be
enhanced by increasing inspired oxygen concentrations, which is
not surprising given the central role of reactive oxygen species in
the generation of adult respiratory distress syndrome. This could
possibly limit the clinical safety of this sort of technique. Have you
done any studies looking at acute lung injury and capillary per-
meability in the lungs of these animals undergoing this combined
treatment?
Dr Baciewicz. You are absolutely right. If you give the animals
too much oxygen, you are obviously going to cause injury from the
oxygen itself. The 1.5-hour period looks to be an optimal amount
of time for treatment. I did not show any histologic images from
the animals that were treated in this study, but the lung tissue
looked normal on histopathologic examination. So we know that
1.5 hours is an acceptable time, but certainly the method of oxygen
administration and the ideal duration remain to be determined.
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